Certain Intravascular Administration Sets and Components Thereof; Issuance of a Limited Exclusion Order Against the Respondent Found in Default; Termination of the Investigation, 37465 [2017-16842]

Download as PDF Federal Register / Vol. 82, No. 153 / Thursday, August 10, 2017 / Notices Coast Guard has published the 60-day notice (82 FR 10375, February 10, 2017) required by 44 U.S.C. 3506(c)(2). That Notice elicited no comments. Accordingly, no changes have been made to the Collections. Information Collection Request Title: National Response Resource Inventory. OMB Control Number: 1625–0102. Summary: The information is needed to improve the effectiveness of deploying response equipment in the event of an oil spill. It may also be used in the development of contingency plans. Need: Section 4202 of the Oil Pollution Act of 1990 (Pub. L. 101–380) requires the Coast Guard to compile and maintain a comprehensive list of spill removal equipment in a response resource inventory (RRI). This collection helps fulfill that requirement. Forms: None. Respondents: Oil spill removal organizations. Frequency: On occasion. Hour Burden Estimate: The estimated burden has decreased from 1,752 hours to 1,378 hours a year. The change in burden is due to a change in the methodology for calculating burden. In past ICRs we did not differentiate between the industry hour burden for inputting a new RRI submission or updating an existing RRI submission. In this ICR, we estimate that it takes fewer hours (i.e., 50 percent fewer hours) to review/update an existing RRI submission than to input a new submission. Authority: The Paperwork Reduction Act of 1995; 44 U.S.C. Chapter 35, as amended. Dated: August 4, 2017. Marilyn L. Scott-Perez, Chief, U.S. Coast Guard, Office of Information Management. [FR Doc. 2017–16869 Filed 8–9–17; 8:45 am] BILLING CODE 9110–04–P INTERNATIONAL TRADE COMMISSION mstockstill on DSK30JT082PROD with NOTICES [Investigation No. 337–TA–1048] Certain Intravascular Administration Sets and Components Thereof; Issuance of a Limited Exclusion Order Against the Respondent Found in Default; Termination of the Investigation U.S. International Trade Commission. ACTION: Notice. AGENCY: Notice is hereby given that the U.S. International Trade SUMMARY: VerDate Sep<11>2014 17:03 Aug 09, 2017 Jkt 241001 Commission has issued a limited exclusion order against certain intravascular administration sets and components thereof of Yangzhou WeiDeLi Trade Co., Ltd. The investigation is terminated. FOR FURTHER INFORMATION CONTACT: Michael Liberman, Esq., Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436, telephone (202) 205–3115. Copies of non-confidential documents filed in connection with this investigation are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436, telephone (202) 205–2000. General information concerning the Commission may also be obtained by accessing its Internet server at https://www.usitc.gov. The public record for this investigation may be viewed on the Commission’s electronic docket (EDIS) at https://edis.usitc.gov. Hearingimpaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205–1810. SUPPLEMENTARY INFORMATION: The Commission instituted this investigation under section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337 (‘‘section 337’’), on April 12, 2017, based on a complaint filed by Curlin Medical Inc. of East Aurora, New York; ZEVEX, Inc. of Salt Lake City, Utah; and Moog Inc. of East Aurora, New York (collectively, ‘‘Complainants’’) (82 FR 17690, April 12, 2017). The complaint alleges a violation of section 337 by reason of infringement of certain claims of U.S. Patent Nos. 6,164,921 (‘‘the ’921 patent’’) and 6,371,732 (‘‘the ’732 patent’’). The complaint named Yangzhou WeiDeLi Trade Co., Ltd. of Yangzhou, China (‘‘Yangzhou’’ or ‘‘Respondent’’) as the only respondent in this investigation. The Commission’s Office of Unfair Import Investigations was named as a party. On May 23, 2017, the ALJ ordered Yangzhou to show cause why it should not be found in default. See Order No. 5. No response to Order No. 5 was filed. On June 13, 2017, the ALJ issued an initial determination finding Yangzhou in default under Commission Rule 210.16(a)(1) (19 CFR 210.16(a)(l)). See Order No. 6. The Commission requested briefing from the parties and the public on the issues of remedy, the public interest, and bonding. The Commission received timely responsive and reply PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 37465 submissions from Complainants and the Commission Investigative Attorney. The submissions agreed that the appropriate remedy is the entry of a limited exclusion order (‘‘LEO’’) against Yangzhou, that the public interest factors do not weigh against granting such a remedy, and that bonding should be set at 100 percent of the entered value of the infringing products. The Commission has determined that the appropriate form of relief in this investigation is a LEO prohibiting the unlicensed entry of intravascular administration sets and components thereof that are covered by one or more of claims 1–3 of the ’732 patent and claims 1–34 of the ’921 patent and that are manufactured abroad by or on behalf of, or imported by or on behalf of, Respondent Yangzhou. The Commission has further determined that the public interest factors enumerated in section 337(g)(l) (19 U.S.C. 1337(g)(l)) do not preclude the issuance of the LEO. Finally, the Commission has determined that the bond for importation during the period of Presidential review shall be in the amount of 100 percent of the entered value of the imported subject articles of Respondent Yangzhou. The Commission’s order was delivered to the President and the United States Trade Representative on the day of its issuance. The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, and in part 210 of the Commission’s Rules of Practice and Procedure, 19 CFR part 210. By order of the Commission. Issued: August 4, 2017. Lisa R. Barton, Secretary to the Commission. [FR Doc. 2017–16842 Filed 8–9–17; 8:45 am] BILLING CODE 7020–02–P INTERNATIONAL TRADE COMMISSION [Investigation Nos. 701–TA–388, 389, and 391 and 731–TA–817, 818, and 821 (Third Review)] Cut-to-Length Carbon Steel Plate From India, Indonesia, and Korea; Scheduling of Full Five-Year Reviews United States International Trade Commission. ACTION: Notice. AGENCY: The Commission hereby gives notice of the scheduling of full reviews pursuant to the Tariff Act of 1930 (‘‘the Act’’) to determine whether revocation SUMMARY: E:\FR\FM\10AUN1.SGM 10AUN1

Agencies

INTERNATIONAL TRADE COMMISSION

[Federal Register Volume 82, Number 153 (Thursday, August 10, 2017)]
[Notices]
[Page 37465]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-16842]


=======================================================================
-----------------------------------------------------------------------

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-1048]


Certain Intravascular Administration Sets and Components Thereof; 
Issuance of a Limited Exclusion Order Against the Respondent Found in 
Default; Termination of the Investigation

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the U.S. International Trade 
Commission has issued a limited exclusion order against certain 
intravascular administration sets and components thereof of Yangzhou 
WeiDeLi Trade Co., Ltd. The investigation is terminated.

FOR FURTHER INFORMATION CONTACT: Michael Liberman, Esq., Office of the 
General Counsel, U.S. International Trade Commission, 500 E Street SW., 
Washington, DC 20436, telephone (202) 205-3115. Copies of non-
confidential documents filed in connection with this investigation are 
or will be available for inspection during official business hours 
(8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. 
International Trade Commission, 500 E Street SW., Washington, DC 20436, 
telephone (202) 205-2000. General information concerning the Commission 
may also be obtained by accessing its Internet server at https://www.usitc.gov.
    The public record for this investigation may be viewed on the 
Commission's electronic docket (EDIS) at https://edis.usitc.gov. 
Hearing-impaired persons are advised that information on this matter 
can be obtained by contacting the Commission's TDD terminal on (202) 
205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation 
under section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337 
(``section 337''), on April 12, 2017, based on a complaint filed by 
Curlin Medical Inc. of East Aurora, New York; ZEVEX, Inc. of Salt Lake 
City, Utah; and Moog Inc. of East Aurora, New York (collectively, 
``Complainants'') (82 FR 17690, April 12, 2017). The complaint alleges 
a violation of section 337 by reason of infringement of certain claims 
of U.S. Patent Nos. 6,164,921 (``the '921 patent'') and 6,371,732 
(``the '732 patent''). The complaint named Yangzhou WeiDeLi Trade Co., 
Ltd. of Yangzhou, China (``Yangzhou'' or ``Respondent'') as the only 
respondent in this investigation. The Commission's Office of Unfair 
Import Investigations was named as a party.
    On May 23, 2017, the ALJ ordered Yangzhou to show cause why it 
should not be found in default. See Order No. 5. No response to Order 
No. 5 was filed. On June 13, 2017, the ALJ issued an initial 
determination finding Yangzhou in default under Commission Rule 
210.16(a)(1) (19 CFR 210.16(a)(l)). See Order No. 6.
    The Commission requested briefing from the parties and the public 
on the issues of remedy, the public interest, and bonding. The 
Commission received timely responsive and reply submissions from 
Complainants and the Commission Investigative Attorney. The submissions 
agreed that the appropriate remedy is the entry of a limited exclusion 
order (``LEO'') against Yangzhou, that the public interest factors do 
not weigh against granting such a remedy, and that bonding should be 
set at 100 percent of the entered value of the infringing products.
    The Commission has determined that the appropriate form of relief 
in this investigation is a LEO prohibiting the unlicensed entry of 
intravascular administration sets and components thereof that are 
covered by one or more of claims 1-3 of the '732 patent and claims 1-34 
of the '921 patent and that are manufactured abroad by or on behalf of, 
or imported by or on behalf of, Respondent Yangzhou. The Commission has 
further determined that the public interest factors enumerated in 
section 337(g)(l) (19 U.S.C. 1337(g)(l)) do not preclude the issuance 
of the LEO. Finally, the Commission has determined that the bond for 
importation during the period of Presidential review shall be in the 
amount of 100 percent of the entered value of the imported subject 
articles of Respondent Yangzhou. The Commission's order was delivered 
to the President and the United States Trade Representative on the day 
of its issuance.
    The authority for the Commission's determination is contained in 
section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, and 
in part 210 of the Commission's Rules of Practice and Procedure, 19 CFR 
part 210.

    By order of the Commission.

    Issued: August 4, 2017.
Lisa R. Barton,
Secretary to the Commission.
[FR Doc. 2017-16842 Filed 8-9-17; 8:45 am]
BILLING CODE 7020-02-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.